Leukapheresis
A patient's white blood cells, including T cells, are extracted through a specialized blood filtration process (leukapheresis). The T cells are then cryopreserved and sent to our manufacturing facility for reprogramming
Cell Infusion
Deliver reprogrammed CAR T cells into the patient's blood Strict quality testing occurs prior to the release and shipment of the CAR T cells back to the patient . Quality Check
How CAR T Therapy Works
Individualized CAR T therapy uses a patient's own immune system to fight certain types of cancers. A patient's T cells are extracted and reprogrammed outside of the body to recognize and fight cancer cells and other cells expressing a particular antigen.
Chimeric Antigen Receptor T Cell ( CAR T ) Therapy

Cell Death
Within the patient's body, the CAR T cells have the potential to recognize the patient's cancer cells and other cells expressing a specific antigen and attach to them, which may initiate direct cell death
Cancer Cell CAR T Cell
CAR T cells attach to cancer cells
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Cell death is initiated
Lymphodepleting chemotherapy
Lymphodepleting chemotherapy is given to the patient to reduce the level of white blood cells and help the body accept the reprogrammed CAR T cells
Newly created CAR T cells undergo expansion
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Manufacturing Facility
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080
For decades, researchers have pursued various ways to utilize the human immune system to fight cancer. Through these researchers' innovation and perseverance, autologous CAR T therapies were discovered.
In contrast to typical small molecule or biologic products, autologous CAR T therapies are specifically manufactured for each individual patient and require a paradigm shift in the approach to manufacturing, logistics and administration.
Through a collaboration with the University of Pennsylvania (Penn), Novartis made an early commitment to the emerging field of CAR T therapies. Its facility in Morris Plains, New Jersey, was the first manufacturing site approved by the FDA for immunocellular therapy production in the US, and has manufactured CAR T cells for hundreds of patients in global clinical trials.
CAR T therapies are manufactured for each individual patient
